(19)
(11) EP 1 492 440 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.07.2008 Bulletin 2008/29

(45) Mention of the grant of the patent:
11.06.2008 Bulletin 2008/24

(21) Application number: 03728350.4

(22) Date of filing: 08.04.2003
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
G01N 33/574(2006.01)
 G01N 33/50(2006.01)
(86) International application number:
PCT/US2003/010745
(87) International publication number:
WO 2003/086174 (23.10.2003 Gazette 2003/43)

(54)

A NEW METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES

NEUES VERFAHREN FÜR DIE DIAGNOSE UND PROGNOSE VON MALIGNEN ERKRANKUNGEN

METHODE DE DIAGNOSTIC ET DE PRONOSTIC DE MALADIES MALIGNES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 08.04.2002 US 118854

(43) Date of publication of application:
05.01.2005 Bulletin 2005/01

(73) Proprietors:
  • UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Louisville, KY 40202 (US)
  • Bates, Paula J.
    Louisville, KY 40207 (US)
  • Miller, Donald M.
    Louisville, KY 40206 (US)
  • Trent, John O.
    Louisville, KY 40207 (US)
  • Xu, Xiaohua
    FL2, Baltimore MD 21211 (US)

(72) Inventors:
  • BATES, Paula, J.
    Louisville, KY 40207 (US)
  • MILLER, Donald, M.
    Louisville, KY 40206 (US)
  • TRENT, John, O.
    Louisville, KY 40207 (US)
  • XU, Xiaohua
    FL2, Baltimore MD 21211 (US)

(74) Representative: MacLean, Martin Robert et al
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ
London EC1N 2SQ (GB)


(56) References cited: : 
WO-A-00/61597
   
  • BATES PAULA J ET AL: "Antiproliferative activity of G-rich oligonucleotides correlates with protein binding" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 37, 10 September 1999 (1999-09-10), pages 26369-26377, XP002168738 ISSN: 0021-9258
  • MI Y ET AL: "Validation of nucleolin as a novel target for cancer drug discovery" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 43, 10 April 2002 (2002-04-10), pages 959-960, XP001182614 ISSN: 0197-016X
  • KWIATKOWSKI B A ET AL: "Identification and cloning of a novel chromatin-associated protein partner of Epstein-Barr nuclear protein 2" EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 300, no. 1, 15 October 2004 (2004-10-15), pages 223-233, XP004571411 ISSN: 0014-4827
  • HOVANESSIAN ET AL: 'The Cell-Surface-Expressed Nucleolin Is Associated with the Actin Cytoskeleton' EXP. CELL. RES. vol. 261, no. 2, December 2000, pages 312 - 328, XP002978746
  • SEMENKOVICH ET AL: 'A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin' BIOCHEMISTRY vol. 29, no. 41, October 1990, pages 9708 - 9713, XP002978747
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).